Literature DB >> 26669328

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.

Eugenia Kraynov1, Amrita V Kamath2, Markus Walles2, Edit Tarcsa2, Antoine Deslandes2, Ramaswamy A Iyer2, Amita Datta-Mannan2, Priya Sriraman2, Michaela Bairlein2, Johnny J Yang2, Matthew Barfield2, Guangqing Xiao2, Enrique Escandon2, Weirong Wang2, Dan A Rock2, Nagendra V Chemuturi2, David J Moore2.   

Abstract

An antibody-drug conjugate (ADC) is a unique therapeutic modality composed of a highly potent drug molecule conjugated to a monoclonal antibody. As the number of ADCs in various stages of nonclinical and clinical development has been increasing, pharmaceutical companies have been exploring diverse approaches to understanding the disposition of ADCs. To identify the key absorption, distribution, metabolism, and excretion (ADME) issues worth examining when developing an ADC and to find optimal scientifically based approaches to evaluate ADC ADME, the International Consortium for Innovation and Quality in Pharmaceutical Development launched an ADC ADME working group in early 2014. This white paper contains observations from the working group and provides an initial framework on issues and approaches to consider when evaluating the ADME of ADCs.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Mesh:

Substances:

Year:  2015        PMID: 26669328     DOI: 10.1124/dmd.115.068049

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  The third annual BRDS on research and development of nucleic acid-based nanomedicines.

Authors:  Amit Kumar Chaudhary; Ram I Mahato
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

Review 3.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

4.  The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.

Authors:  Amita Datta-Mannan; Hiuwan Choi; David Stokell; Jason Tang; Anthony Murphy; Aaron Wrobleski; Yiqing Feng
Journal:  AAPS J       Date:  2018-09-25       Impact factor: 4.009

5.  Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.

Authors:  Hsuan-Ping Chang; Zhe Li; Dhaval K Shah
Journal:  Pharm Res       Date:  2022-01-19       Impact factor: 4.200

6.  Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.

Authors:  Vincent Chen; Shigeki Umemura; Yumin Han; Renuka Raman; Robin Tucker; Joeffrey Chahine; In-Kyu Kim; Christoph Schatz; Sabine Zitzmann-Kolbe; Anette Sommer; Masanori Onda; Trevor Lee; Yongfeng He; Giuseppe Giaccone
Journal:  Br J Cancer       Date:  2021-12-07       Impact factor: 9.075

7.  High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody-Drug Conjugate Aggregation and Drug Release.

Authors:  Kenneth R Durbin; M Shannon Nottoli; Nathaniel D Catron; Nicole Richwine; Gary J Jenkins
Journal:  ACS Omega       Date:  2017-08-03

Review 8.  Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates.

Authors:  Xiaoyu Zhu; Shihan Huo; Chao Xue; Bo An; Jun Qu
Journal:  J Pharm Anal       Date:  2020-05-23

Review 9.  Current status and future directions of high-throughput ADME screening in drug discovery.

Authors:  Wilson Z Shou
Journal:  J Pharm Anal       Date:  2020-05-23

Review 10.  Antibody Conjugates-Recent Advances and Future Innovations.

Authors:  Donmienne Leung; Jacqueline M Wurst; Tao Liu; Ruben M Martinez; Amita Datta-Mannan; Yiqing Feng
Journal:  Antibodies (Basel)       Date:  2020-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.